Literature DB >> 16408211

Effect of interleukin-18 on metastasis of mouse osteosarcoma cells.

Yoshiteru Nakamura1, Naoko Yamada, Hideki Ohyama, Keiji Nakasho, Yasuko Nishizawa, Takuya Okamoto, Hiroyuki Futani, Shinichi Yoshiya, Haruki Okamura, Nobuyuki Terada.   

Abstract

The effect of interleukin-18 (IL-18) on metastasis of highly metastatic LM8 mouse osteosarcoma cells was investigated using nude mice treated with anti-asialo GM1 serum to exclude anti-tumor actions of IL-18 through activation of T and natural killer cells. Injection of LM8 cells which do not express IL-18 receptor beta into a tail vain resulted in the formation of pulmonary and hepatic metastatic foci. Daily injection of mice with IL-18 starting the fifth day from the cell injection had no significant effect on the number of metastatic foci, while five daily injections of IL-18 before and after the cell injection resulted in marked decreases. Culture of LM8 cells with IL-18 for 5 days before the injection into mice produced no significant effect on the number of pulmonary and hepatic metastatic foci. In contrast, pretreatment of mice with IL-18 for 5 days before the cell injection markedly decreased metastatic foci. The retention of LM8 cells in the lung 24 h after their injection was also reduced by the pretreatment of mice with IL-18. Serum obtained from mice pretreated with IL-18 for 5 days suppressed mobility of LM8 cells but IL-18 itself did not. These results suggest that IL-18 inhibits metastasis of LM8 cells partly by inducing a factor(s) in the host which suppresses cell mobility.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16408211     DOI: 10.1007/s00262-005-0097-3

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  8 in total

1.  Effect of lentiviral vector-packaged interleukin-18 gene on the malignant behavior of lung cancer.

Authors:  Xiangqi Chen; Rui Feng; Donglan Xiong; Sheng Yang; Tingyan Lin
Journal:  Exp Ther Med       Date:  2019-11-15       Impact factor: 2.447

2.  Human IL18-IL2 fusion protein as a potential antitumor reagent by enhancing NK cell cytotoxicity and IFN-γ production.

Authors:  Guangying Du; Liang Ye; Guoying Zhang; Qiuju Dong; Kun Liu; Jingwei Tian
Journal:  J Cancer Res Clin Oncol       Date:  2012-06-15       Impact factor: 4.553

3.  Hypoxia-induced IL-18 increases hypoxia-inducible factor-1alpha expression through a Rac1-dependent NF-kappaB pathway.

Authors:  Jeongki Kim; Yan Shao; Sang Yong Kim; Seyl Kim; Hyun Keun Song; Jun Ho Jeon; Hyun Woo Suh; Jin Woong Chung; Suk Ran Yoon; Young Sang Kim; Inpyo Choi
Journal:  Mol Biol Cell       Date:  2007-11-14       Impact factor: 4.138

Review 4.  Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature.

Authors:  J PosthumaDeBoer; M A Witlox; G J L Kaspers; B J van Royen
Journal:  Clin Exp Metastasis       Date:  2011-04-02       Impact factor: 5.150

5.  Molecular alterations associated with osteosarcoma development.

Authors:  Kosei Ando; Kanji Mori; Franck Verrecchia; Baud'huin Marc; Françoise Rédini; Dominique Heymann
Journal:  Sarcoma       Date:  2012-02-15

6.  Immunologic Function and Molecular Insight of Recombinant Interleukin-18.

Authors:  Jirakrit Saetang; Aekkachai Puseenam; Niran Roongsawang; Supayang Piyawan Voravuthikunchai; Surasak Sangkhathat; Varomyalin Tipmanee
Journal:  PLoS One       Date:  2016-08-02       Impact factor: 3.240

7.  Relationship of common variants in Interleukin 33 gene with susceptibility and prognosis of osteosarcoma in Han Chinese population.

Authors:  Chao Kang; Jianwu Zhao; Yuanchun Wang; Chenguang Yang; Jie Chen; Liqiang Zhi
Journal:  J Cancer       Date:  2019-01-29       Impact factor: 4.207

Review 8.  Gene-Edited Interleukin CAR-T Cells Therapy in the Treatment of Malignancies: Present and Future.

Authors:  Zhengchao Zhang; Lele Miao; Zhijian Ren; Futian Tang; Yumin Li
Journal:  Front Immunol       Date:  2021-07-27       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.